Brachytherapy Market Size

 Brachytherapy Market Overview

The Brachytherapy Market was valued at USD 0.98 billion in 2023. The industry is projected to grow from USD 1.07 billion in 2024 to USD 1.94 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 6.84% during the forecast period (2024 - 2032). The increasing incidences of cancer across the globe and increasing number of product launch are driving the market growth.

Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review

Brachytherapy Market Trends

Increasing incidences of cancer across the globe.

The introduction of brachytherapy services is significantly boosting the growth of the Brachytherapy Market by enhancing treatment options for cancer patients. As healthcare facilities expand their offerings to include this targeted, minimally invasive approach, they attract more patients seeking effective alternatives to traditional radiation therapy. Brachytherapy's ability to deliver concentrated doses of radiation directly to tumors while preserving healthy tissue is improving patient outcomes and satisfaction.

Additionally, shorter treatment times and reduced side effects are encouraging adoption among both patients and healthcare providers. In September 2024, Karnataka Medical College and Research Institute (India) launched brachytherapy services, a significant advancement in treating esophageal and cervical cancers. The new machine, acquired for USD 0.77 million, is the latest generation of brachytherapy equipment. Further, the institute is the first government medical college in the state to have such advanced technology, filling a critical gap in North Karnataka where similar services are not available in private hospitals. Previously, patients requiring brachytherapy were referred to institutions in Bengaluru and Hubballi. 

Additionally, In June 2023, Universitas Academic Complex in Bloemfontein has made history as the first facility in Southern Africa to use interstitial brachytherapy for treating cervical cancer. This milestone was achieved by a multidisciplinary team, including

anaesthetists, oncologists, medical physicists, and nurses, who successfully completed the procedure in June 2023. Interstitial brachytherapy involves placing a radiation source directly inside or near the tumor, allowing for high doses to be delivered precisely while minimizing exposure to surrounding healthy tissues. UFS Department of Oncology, highlighted that this technique builds on decades of research, combining intracavitary and interstitial methods to improve treatment outcomes for locally advanced cervical cancers. This innovative approach positions UFS at the forefront of cancer treatment in the region.

Brachytherapy Market Segment Insights:

Global Brachytherapy Product Insight

Based on Product, the Brachytherapy Market has been segmented into Afterloaders & Applicators, Radioactive Seeds, Electronic Brachytherapy, Imaging Systems, and Others. The radioactive seeds segment held the largest market in 2023 and the electronic brachytherapy segment is the fastest growing segment during the forecast period. 

The afterloaders and applicators market is growing rapidly due to advancements in cancer treatments and the rising global prevalence of cancer. Afterloaders, which automate the placement of radioactive sources in brachytherapy, improve treatment precision and patient safety, making them increasingly popular in clinical settings. The demand for specialized applicators for cancers like prostate and cervical cancer is also increasing. Key players like Varian, with their Bravos afterloader system for high-dose-rate brachytherapy, are innovating to improve workflow and patient outcomes. As awareness of brachytherapy's benefits, such as shorter treatment times and fewer side effects, grows, the market is expected to continue expanding.

The radioactive seeds market, primarily used for prostate brachytherapy, is growing due to their ability to provide precise, localized treatment with minimal impact on surrounding tissues. Increased awareness of this minimally invasive approach is driving demand. Innovations in seed technology, such as Isoray Inc.'s Cs-131 seed with a shorter half-life and faster radiation delivery, are improving treatment efficacy and safety. As personalized medicine and cancer care improve, the market for brachytherapy seeds is expected to expand.

Electronic brachytherapy, offering benefits like improved safety and reduced radiation exposure, is gaining acceptance for treating various cancers, including breast, skin, and cervical cancers. Devices like Esteya and Photoelectric Therapy are effective for small skin cancers. Ongoing advancements in treatment technologies, research, and strategic partnerships are fueling market growth, making electronic brachytherapy solutions more accessible and ensuring continued expansion.

Imaging technologies are vital for accurate tumor localization and dosimetry in brachytherapy, ensuring precise placement of radioactive sources. The increasing prevalence of cancer, especially in developing regions, is driving healthcare providers to adopt advanced imaging solutions for better treatment outcomes. Innovations like real-time imaging and integration with planning software are enhancing the efficiency of brachytherapy. As awareness of targeted therapies grows and investments in healthcare infrastructure increase, the brachytherapy imaging systems market is expected to expand, creating new opportunities for industry players.

Additionally, innovations in software, specialized needles, and fiducial markers are improving treatment planning, precision, and tumor localization. The growing adoption of minimally invasive treatments and ongoing research supporting the effectiveness of brachytherapy are further fueling market growth.

Figure 2: BRACHYTHERAPY MARKET SIZE, BY PRODUCT, 2023 & 2032 (USD Billion)

Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review

Global Brachytherapy Type Insights

Based on Type, the Brachytherapy Market has been segmented into High dose-rate (HDR) brachytherapy and Low dose-rate (LDR) brachytherapy. The high dose-rate (HDR) brachytherapy segment held the largest market in 2023 and the same segment is the fastest growing segment during the forecast period.

The high dose-rate (HDR) brachytherapy is being driven by advances in cancer treatment technology. HDR brachytherapy, noted for its precision and efficiency, enables targeted radiation delivery while minimizing damage to surrounding tissues. Rising awareness of minimally invasive procedures, enhanced healthcare infrastructure, and ongoing research and development are all major drivers of market growth. Furthermore, agreements between medical device manufacturers and healthcare providers improve product

options. As the demand for individualized cancer therapies continues to rise, the HDR brachy therapy market is poised for continued expansion in the future years.

Low dose-rate (LDR) brachytherapy, which involves inserting radioactive sources directly into or around a tumour, provides accurate treatment while causing minimal injury to surrounding tissues. Low-dose rate brachytherapy can be an effective treatment for any patient, regardless of age or cancer risk level.

Global Brachytherapy Technique Insights

Based on Technique, the Brachytherapy Market has been segmented into Interstitial brachytherapy and intracavity brachytherapy. The Interstitial brachytherapy segment held the largest market in 2023 and the same segment is the fastest growing segment during the forecast period.

The interstitial brachytherapy technique market is experiencing significant growth, driven by advancements in cancer treatment and increased awareness of the benefits of localized therapy. This technique involves placing radioactive sources directly into or near tumors, allowing for targeted radiation delivery while minimizing exposure to surrounding healthy tissue. Factors contributing to market expansion include rising cancer incidences, technological innovations in brachytherapy devices, and supportive government initiatives. Moreover, the growing prevalence of prostate and breast cancer is fueling demand for effective treatment options.

Intracavity brachytherapy technique market is poised for robust growth due to favorable government regulations and funding for cancer treatment programs are further stimulating market demand. As the focus on personalized medicine continues to grow, the intracavity brachytherapy market is expected to see continued innovation and investment, enhancing treatment outcomes.

Global Brachytherapy Indication Insights

Based on Indication, the Brachytherapy Market has been segmented into Prostate Cancer, Breast Cancer, Cervical Cancer, Skin Cancer, and Others. The prostate segment held the largest market in 2023 and the same segment is the fastest growing segment during the forecast period.

The prostate cancer brachytherapy market is experiencing significant growth, driven by the increasing incidence of prostate cancer and advancements in treatment technologies. According to the American Cancer Society, in 2024, there will be around 299,010 new cases of prostate cancer and 35,250 deaths from prostate cancer. Brachytherapy, a minimally invasive procedure, offers targeted radiation therapy, reducing side effects compared to traditional treatments. Rising awareness among patients and healthcare providers about the benefits of brachytherapy is further propelling market expansion.

Breast cancer indications are experiencing significant growth, driven by the rising incidence of breast cancer and advancements in brachytherapy techniques. This targeted radiation therapy offers patients reduced treatment times and lower exposure to surrounding healthy tissue, making it an attractive option for localized tumors. Increased awareness among patients and healthcare providers about the benefits of brachytherapy is propelling demand. According to the World Health Organisation, 2.3 million women were diagnosed with breast cancer in 2022, with 670,000 fatalities worldwide which will drive the demand for brachytherapy Market.

Cervical cancer is experiencing substantial growth, driven by advancements in brachytherapy techniques. This targeted treatment method delivers radiation directly to the tumor, minimizing damage to surrounding healthy tissue and enhancing patient outcomes. Increasing awareness about the effectiveness of brachytherapy among healthcare providers and patients is boosting demand.

Rising awareness of skin cancer risks, coupled with an aging population and the prevalence of high-risk factors such as UV exposure, is propelling market demand. Additionally, growing investments in research and development, alongside the introduction of innovative brachytherapy devices, are expected to further enhance treatment options. As healthcare providers increasingly adopt personalized medicine approaches, the brachytherapy market is poised for continuous expansion globally. According to the American Academy of Dermatology Association, skin cancer will be the most frequent cancer in the United States by 2024. It is estimated that roughly 9,500 persons in the United States are diagnosed with skin cancer each day. 

Others include Lung Cancer, Head and Neck Cancer, Eye Cancer, and Gallbladder Cancer. The Brachytherapy Market for cancer treatment, encompassing lung, neck, eye, and gallbladder cancers, is witnessing significant growth due to advancements in technology and rising incidences of these malignancies. Brachytherapy, a form of internal radiation therapy, allows for targeted treatment with minimal damage to surrounding healthy tissues, making it a preferred option for many patients. Key players in this market are focusing on developing innovative products and enhancing delivery mechanisms to improve patient outcomes. The rise in awareness about cancer treatment options and the increasing adoption of minimally invasive procedures are further propelling market growth. Additionally, the integration of imaging technologies in brachytherapy procedures is expected to enhance precision and effectiveness. As healthcare systems continue to prioritize personalized medicine, the brachytherapy market for these specific cancers is poised for significant expansion in the coming years.

Global Brachytherapy End-Users Insights

Based on End User, the Brachytherapy Market has been segmented into Hospitals and Specialty Clinics, Cancer Treatment Centers, and Others. The hospitals and specialty clinics segment held the largest market in 2023, and the cancer treatment centers segment is the fastest growing segment during the forecast period.

Hospitals and specialty clinics are primary end users, as they offer advanced diagnostic and treatment options. The rise in outpatient procedures and the demand for personalized medicine further enhance the market's growth. Additionally, the expanding awareness of brachytherapy's benefits, such as shorter recovery times and targeted radiation delivery, encourages more facilities to adopt these techniques. As healthcare providers continue to invest in innovative solutions, the brachytherapy market is poised for significant expansion in the coming years.

Cancer treatment centers are key end users, leveraging brachytherapy for its precision and efficacy in localized cancer treatment. The shift towards personalized medicine and advanced imaging techniques enhances the appeal of brachytherapy, enabling tailored therapies for patients. Additionally, the integration of cutting-edge technologies and increased awareness of brachytherapy's benefits, such as reduced side effects and shorter recovery times, drives adoption in these centers.

Other end users such as Academic and research institutes, which drive innovation through clinical trials and studies. These institutions play a crucial role in advancing brachytherapy techniques and exploring new applications, fueled by the increasing prevalence of cancer. The focus on research fosters the development of more effective and targeted therapies, enhancing treatment outcomes.

Global Brachytherapy Regional Insights

Based on the region, the Brachytherapy Market has been segmented into North America, Europe, Asia-Pacific, and Rest of the World. North America accounted for the largest market share in 2023. However, Asia-Pacific is projected to grow at the highest CAGR of 7.98% during the forecast period.

The brachytherapy market in North America is rapidly evolving, reflecting significant advancements in cancer treatment approaches. As cancer rates rise, particularly for localized forms such as prostate, breast, and cervical cancers, the demand for effective therapies has surged. According to the American Cancer Society, there are projected to be approximately 299,010 new cases of prostate cancer in the US in 2024. Prostate cancer causes about 35,250 deaths annually. Moreover, In the United States, breast cancer is the most prevalent cancer to be diagnosed in women. Breast cancer accounts for almost 30% of all newly diagnosed cancers in women each year. Furthermore, According to Centers for Disease Control and Prevention every year in the United States, approximately 11,500 new cases of cervical cancer are diagnosed, and approximately 4,000 women die as a result of the cancer. Brachytherapy stands out due to its ability to deliver high doses of radiation directly to the tumor site, thereby minimizing exposure to surrounding healthy tissue and reducing side effects. This targeted approach not only enhances treatment efficacy but also aligns with patient preferences for minimally invasive procedures and quicker recovery times. 

The brachytherapy market in Europe is experiencing significant growth, driven by technological advancements, such as improved imaging and delivery systems, enhance the precision and outcomes of brachytherapy, making it a preferred choice for many healthcare providers. For instance, according to Eurostat, in January 2023, the EU population was predicted to be 448.8 million people, with more than a fifth (21.3%) of them aged 65 and up. Ongoing research and clinical trials continue to explore new applications for brachytherapy, expanding its potential uses and effectiveness.  Furthermore, the emphasis on personalized medicine in oncology aligns  well with brachytherapy’s targeted approach, solidifying its role in modern cancer treatment. Moreover, Innovations in brachytherapy techniques and equipment, such as high-dose-rate (HDR) systems and improved imaging technologies, enhance treatment precision and safety, making it more appealing to healthcare providers. For instance, Elekta (Europe) acquired Xoft business from iCAD, Inc. via asset acquisition. Elekta, the world leader in brachytherapy solutions, can offer electronic brachytherapy technology as well as a wider range of cancer treatment choices after acquiring the Xoft Axxent Electronic Brachytherapy (eBx) System and transferring workers.

The Asia-Pacific brachytherapy market is experiencing robust growth, driven by several interrelated factors. A significant increase in cancer incidence, particularly for breast, prostate, and cervical cancers, has heightened the demand for effective treatment options.  For instance, according to the National Institute of Health, nearly half (45.4%) of the 2.3 million breast cancers (BC) diagnosed in 2020 were from Asia.  This rising prevalence is coupled with substantial investments in healthcare infrastructure, as many countries in the region establish specialized cancer treatment centers, enhancing access to advanced therapies. Technological integration, including advancements in robotics and artificial intelligence for treatment planning, is enhancing the precision and outcomes of these therapies. Government health policies aimed at improving cancer care and access to modern treatment modalities are further promoting brachytherapy use. Additionally, the rise of medical tourism in countries like India and Thailand is boosting demand for specialized cancer treatments, including brachytherapy.

Furthermore, Rest of the world is further divided into Middle East & Africa and South America. Economic development across the region has led to increased healthcare spending, allowing for better access to advanced cancer treatment options. Additionally, international aid and investments are playing a crucial role in enhancing healthcare services, promoting the adoption of modern technologies like brachytherapy. As the patient demographic evolves, with an aging population and rising cancer rates due to lifestyle changes, the demand for effective treatment solutions has intensified. The expansion of health insurance coverage in several countries further improves access to these specialized therapies.

Figure 3: BRACHYTHERAPY MARKET BY REGION 2023 & 2032 (USD Billion)

Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review

Global Brachytherapy Key Market Players & Competitive Insights

The Brachytherapy Market is distinguished by the presence of numerous regional and local players catering to the global brachytherapy products market. Furthermore, increasing incidences of cancer across the globe and increasing number of product launches are the major factors driving the growth of the Brachytherapy Market. 

The Brachytherapy Market is extremely competitive, with players competing and investing heavily in the development of innovative products to gain a significant market share. The market is moderately fragmented with high competition in the market, increasing acquisitions, product launch, and other strategic decisions to achieve operational efficiency. 

The growth of prominent industry players is dependent on various factors, such as market conditions, product differentiation and innovation, and pricing strategies. It is also projected that technological advancements associated with brachytherapy are anticipated to create lucrative opportunities for the market.

Major players in the Brachytherapy Market, including Elekta, Siemens Healthineers AG, BEBIG Medical Gmbh, Theragenics Corporation, Eckert & Ziegler and others are making investments in R&D activities to boost market demand.

For Instance, Eckert & Ziegler is a global leader in isotope technology, focusing on medical, scientific, and industrial applications. The company has grown significantly over the years, becoming a major participant in cancer therapy, industrial radiometry, and nuclear medical diagnostics. Eckert & Ziegler has two major business segments: medical and isotope products. The Medical Segment specializes on offering high-quality products and services for nuclear medicine, radiotherapy, and other applications. The company's product line includes radiopharmaceuticals like Yttriga and GalliaPharm, radiosynthesis technology like Modular-Lab and KitLab, and radiochromatography equipment like the AR-2000 TLC Scanner. Eckert & Ziegler also provides contract manufacturing services, customizing solutions for clinical and commercial supply projects that use alpha, beta, or gamma radiation.

Moreover, In March 2024, Eckert and Ziegler BEBIG GmbH, an Eckert & Ziegler SE company that specializes in brachytherapy solutions for the treatment of prostate cancer, as well as brain and ocular cancers, was one of the first companies in its field received an MDR certificate from DEKRA Certification B.V. for their patented prostate seeds. This significant milestone ensures a high degree of patient safety and the long-term availability of seeds in the EU.

Key Companies in the Brachytherapy Market include.

• Elekta (Sweden)


• BEBIG Medical Gmbh (Germany)


• Theragenics Corporation (US)


• Siemens Healthineers AG (Germany)


• Eckert & Ziegler (Germany)


• Becton, Dickinson and Company (US)


• GE Healthcare (US)


• Merit Medical Systems (US)


• Best Medical International, Inc. (US)


• IsoAid, LLC (US)

Global Brachytherapy Industry Developments

July 2024: GE Healthcare’s MIM software has launched MIM Symphony HDR Prostate, an innovative solution designed to enhance high dose-rate (HDR) brachytherapy. This tool aims to boost clinician confidence and improve patient outcomes by enabling direct tumor visualization from magnetic resonance imaging (MRI) scans during live ultrasound procedures for HDR prostate treatments. By integrating these imaging capabilities, MIM Symphony HDR Prostate supports more precise and effective treatment planning and delivery.

March 2024: Eckert and Ziegler BEBIG GmbH, an Eckert & Ziegler SE company that specializes in brachytherapy solutions for the treatment of prostate cancer, as well as brain and ocular cancers, was one of the first companies in its field received an MDR certificate from DEKRA Certification B.V. for their patented prostate seeds. This significant milestone ensures a high degree of patient safety and the long-term availability of seeds in the EU.

February 2024: Merit Medical Systems recently announced that it has received FDA 510(k) clearance for its Scout MD surgical guidance system. This innovative system e pands the company’s oncolo y portfolio and is designed to enhance the diagnosis and treatment of breast cancer, as well as other soft tissue cancers. The Scout MD includes the Scout radar localization system, which works in conjunction with the Scout mini reflector and the Scout Bx delivery system. Additionally, it features the Savi brachytherapy system, further integrating advanced technology into cancer care.

October 2023: Elekta announced that it has purchased the Xoft business from iCAD, Inc. via asset acquisition. Elekta, the world leader in brachytherapy solutions, has expanded its cancer treatment options by acquiring the Xoft Axxent Electronic Brachytherapy (eBx) System and transferring workers.

Brachytherapy Market Segmentation:

Global Brachytherapy Product Outlook

• Afterloaders & Applicators


• Radioactive Seeds


• Electronic Brachytherapy


• Imaging Systems


• Others

Global Brachytherapy Type Outlook

• High Dose-Rate (HDR) Brachytherapy


• Low Dose-Rate (LDR) Brachytherapy

Global Brachytherapy Technique Outlook

• Interstitial Brachytherapy


• Intracavitary Brachytherapy

Global Brachytherapy Indication Outlook

• Prostate Cancer


• Breast Cancer


• Cervical Cancer


• Skin Cancer


• Others

Global Brachytherapy End-users Outlook

• Hospitals & Specialty Clinics


• Cancer Treatment Centers


• Others

Global Brachytherapy Regional Outlook

• North America
  
  
  
  • US
  
  
  • Canada
  
  
  • Mexico
  
  
  
  


• Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • South Korea
  
  
  • Australia
  
  
  • Rest of Asia-Pacific
  
  
  
  


• Rest of the World
  
  
  
  • Middle East
  
  
  • Africa
  
  
  • South America